EWA
CLRB icon

EverSource Wealth Advisors’s Cellectar Biosciences CLRB Stock Holding History

EverSource Wealth Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-55
Closed -$519 – 4271
2025
Q1 		$519 Buy
+55
New +$498 ﹤0.01% 3447

Other funds holding CLRB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
RCA
Riverview Capital Advisers Boston, Massachusetts $300M AUM 10.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

EverSource Wealth Advisors's CLRB Position: Q2 2025 in Review

EverSource Wealth Advisors sold out of Cellectar Biosciences (CLRB) in Q2 2025, closing a stake of 55 shares — an estimated $519 sold.

EverSource Wealth Advisors first reported a position in CLRB in Q1 2025 and held it in 1 quarter. The position peaked at $519 in Q1 2025. 19 funds tracked by Wall St. Rank hold CLRB as of Q2 2025.

  • EverSource Wealth Advisors reported no remaining Cellectar Biosciences position as of Q2 2025 after selling out during the quarter.
  • EverSource Wealth Advisors sold 55 Cellectar Biosciences shares in Q2 2025, an estimated $519.
  • EverSource Wealth Advisors first reported a position in Cellectar Biosciences in Q1 2025 and held it in 1 quarter.
  • EverSource Wealth Advisors's Cellectar Biosciences position peaked at $519 in Q1 2025.
  • 19 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q2 2025.

Based on EverSource Wealth Advisors's 13F filing for Q2 2025, filed 13 Aug 2025.